tert-butyl N-[4-(6,7-difluoro-2,4-dioxo-1H-quinazolin-3-yl)phenyl]carbamate | 936500-98-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-[4-(6,7-difluoro-2,4-dioxo-1H-quinazolin-3-yl)phenyl]carbamate
• CAS: 936500-98-0
• 化学式: C₁₉H₁₇F₂N₃O₄
• 分子量: 389.358
• InChiKey: MTXRLJCAOYKSEE-UHFFFAOYSA-N

物化性质

• 密度：
  1.400±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[4-(6,7-difluoro-2,4-dioxo-1H-quinazolin-3-yl)phenyl]carbamate 在 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二甲基亚砜 为溶剂， 反应 28.67h， 生成 [4-(6-chloro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea tromethamine salt
  参考文献：
  名称：

  WO2008/137809

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氨基-4,5-二氟苯甲酸甲酯 在 甲醇 、 sodium methylate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.75h， 生成 tert-butyl N-[4-(6,7-difluoro-2,4-dioxo-1H-quinazolin-3-yl)phenyl]carbamate
  参考文献：
  名称：

  WO2008/137809

  摘要：

  公开号：

文献信息

• [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO
  申请人：Scarborough Robert

  公开号：US20070123547A1

  公开（公告）日：2007-05-31

  The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

  本发明提供了式（I）的新型磺酰脲化合物及其药学上可接受的衍生物、多晶型和非晶态形式。这些化合物在其各种形式下是有效的血小板ADP受体抑制剂，可用于各种制药组合物中，并且特别有效于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病。本发明还提供了一种制备这样的化合物和形式以及在哺乳动物中预防或治疗血栓形成和与血栓形成有关的疾病的方法，包括给予式（I）的化合物或其药学上可接受的盐或形式的治疗有效量。
• [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO
  申请人：Sharp Emma

  公开号：US20090042916A1

  公开（公告）日：2009-02-12

  The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.

  本发明提供了一种盐酸式(I)盐的磺酰脲盐及其多晶形式。这些化合物在其各种形式下都是有效的血小板ADP受体抑制剂，可用于各种药物组合物中，并且特别有效用于预防和/或治疗心血管疾病，特别是与血栓相关的疾病。本发明还提供了一种制备这些化合物和形式以及在哺乳动物中预防或治疗血栓和与血栓相关疾病的方法，包括给予公式(I)的盐或其药学上可接受的形式的治疗有效量。
• INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR
  申请人：Gretler Daniel D.

  公开号：US20090048216A1

  公开（公告）日：2009-02-19

  The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.

  该发明提供了一种用于快速和可逆地抑制人体内需要的血小板聚集的方法和组合物，通过给予以下化合物的方式：单独或与第二药物联合使用，第二药物可以是阿司匹林或溶栓剂。
• SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF
  申请人：Scarborough M. Robert

  公开号：US20070208045A1

  公开（公告）日：2007-09-06

  The present invention provides sulfonylurea compounds of formula (VIII) and pharmaceutically acceptable derivatives thereof and a process for making thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and salts or prodrugs thereof. The invention also provides a method for inhibition platelet ADP receptor and preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (VIII) or a pharmaceutically acceptable salt or forms thereof.

  本发明提供了式（VIII）的磺酰脲化合物及其药学上可接受的衍生物以及制备它们的方法。这些化合物在各种形式下均是有效的血小板ADP受体抑制剂，可用于各种制药组合物中，特别是对于预防和/或治疗心血管疾病，特别是与血栓形成相关的疾病非常有效。本发明还提供了在该过程中有用的中间化合物，以及该过程产生的最终产品，以及其盐或前药。本发明还提供了一种用于抑制血小板ADP受体并预防或治疗哺乳动物中的血栓和与血栓相关疾病的方法，包括给予式（VIII）的化合物或其药学上可接受的盐或形式的治疗有效量的步骤。
• [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto
  申请人：Scarborough Robert

  公开号：US20120088736A1

  公开（公告）日：2012-04-12

  The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

  本发明提供了式（I）的新型磺酰脲化合物及其药学上可接受的衍生物、多晶形式和非晶形式。这些化合物在其各种形式下均为有效的血小板ADP受体抑制剂，可用于各种制药组合物中，并且特别有效于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病。本发明还提供了制备这些化合物和形式的方法，并用于在哺乳动物中预防或治疗血栓形成和与血栓形成相关的疾病，包括给予式（I）化合物或其药学上可接受的盐或形式的治疗有效量。